Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Interim Management Statement

17 Nov 2011 07:00

RNS Number : 2518S
Tarsus Group PLC
17 November 2011
 



17 November 2011

TARSUS GROUP plc

 

Interim Management Statement

 

Tarsus Group plc (LSE: TRS, "Tarsus" or "the Group"), the international business-to-business media group, is today publishing its Interim Management Statement for the period from 1 July 2011 to 16 November 2011.

 

Trading

 

Trading and forward bookings for the year to 31 December 2011 remain very positive with the Group on track to meet the Board's expectations. Forward bookings now stand at 96% of anticipated full year revenues compared to 93% at the same time in 2010 (as adjusted for biennial events).

 

As a result of the timing of exhibitions, the fourth quarter of 2011 is highly cash generative and we are on track for year end net debt to be in line with management expectations.

 

Emerging markets

 

The Group's emerging markets business has continued to gain momentum with strong revenue growth.

 

This week we are holding the Group's largest event, the Dubai Airshow, which is on track to be a record show. At the opening of the show, Emirates Airlines announced that it had ordered 50 long-range Boeing 777-300 ER passenger jets worth a combined $18 billion, in addition to an option over 20 further planes worth a combined $8 billion, taking the total value of firm orders and options to $26 billion. This is the single largest dollar-value order in Boeing's history. Total plane orders for the show currently stand at $55 billion, a large increase on the $14 billion of total new orders announced at the previous edition of the Dubai Air Show in 2009.

 

We expect the Air Show to attract a record number of trade visitors and 960 exhibitors from 50 countries attended. The five day show, which ends today, is one of the world's largest and fastest growing Air Shows. The 2013 exhibition will move to a larger facility at the new Al-Maktoum International Airport in Dubai.

 

Trading in the Chinese business continues to be very strong. Tarsus is on course for a record Labelexpo Asia at the end of this month.

 

The integration of IFO in Turkey, acquired in June 2011, is going well. Sales for IFO's next exhibition, Sign Istanbul in early December, are tracking well ahead of the 2010 edition.

 

US

 

As previously indicated, the August 2011 Off-Price Show in Las Vegas performed well, with revenues up 6%. The broadening of the offer to retailers by the inclusion of footwear and accessories has been a major factor in this division's continued success. Bookings for the February 2012 show are tracking ahead of the February 2011 edition.

 

The Medical division has continued to grow strongly, at a double digit rate. This has been driven by its education programmes, including those now delivered online. The 2012 order book is strong.

 

Europe

 

Labelexpo Europe, the Group's second largest show, took place in September in Brussels. It produced a like-for-like revenue increase of 13% and a record attendance, with an improvement of over 18% compared with its 2009 edition. As a result of this strong performance, re-bookings for the 2013 exhibition of 81% were secured. On-site sales for the other Labels events were at record levels.

 

On 3 October 2011 Tarsus announced that it has reached agreement to sell its 51% interest in its French joint venture, ModAmont SAS, to its partner, Premiere Vision SAS, for a total consideration of approximately €6.1 million in cash. The disposal is subject to and conditional upon the approval of shareholders of the Group at a general meeting due to be held on 28 November 2011 and the disposal is expected to complete in early December 2011.

 

Trading in France has been in line with the Board's expectations. The Group's larger French exhibitions have stabilised, the markets are challenging for the smaller ones. The disposal of ModAmont will materially reduce the Group's exposure to the lower growth European market. Following the disposal, less than 10% of Group profits are expected to be generated from France. Tarsus France will continue to focus on its remaining wholly-owned portfolio of exhibitions.

 

Douglas Emslie, Tarsus Group Managing Director, said:

 

"This year has the hallmarks of being a record year. Our forward bookings continue to be strong and we are well on track to meet our expectations for 2011.

 

"We remain committed to our long term strategy of increasing our exposure to emerging markets (Project 50/13 - whereby 50% of our revenue will be sourced from emerging markets by 2013) and driving organic growth across the business. It is already yielding results with the notable growth of the Dubai Air Show and the acquisition of IFO in Turkey.

 

"Looking forward to 2012, we are encouraged by the momentum of our US Medical business, Off-Price events and Labelexpo Americas, but remain vigilant owing to the second half weighting of our profits. The momentum we have built across both Middle and Far Eastern markets in 2011 augurs well for 2013 when the large biennial events recur."

 

The Group expects to publish a year end trading update on 5 January 2012.

 

For further information:

 

Tarsus Group plc:

Douglas Emslie, Group Managing Director 020 8846 2700

Dan O'Brien, Group Finance Director

 

Media

Madano Partnership:

Matthew Moth 020 7593 4000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSDKADKFBDDADD
Date   Source Headline
16th May 20197:00 amRNSTrading Update
9th May 20196:19 pmRNSBlock Listing Six Monthly Return
30th Apr 201910:14 amRNSTotal Voting Rights
16th Apr 20192:40 pmRNSDirector/PDMR Shareholding
2nd Apr 20193:43 pmRNSBlock listing Interim Review
1st Apr 201910:44 amRNSTotal Voting Rights
19th Mar 201911:42 amRNS2018 Annual Report
8th Mar 20194:36 pmRNSPrice Monitoring Extension
27th Feb 20197:00 amRNSFinal Results
6th Feb 20194:35 pmRNSPrice Monitoring Extension
31st Jan 201911:53 amRNSTotal Voting Rights
30th Jan 20197:00 amRNSOption agreement re Tarsus Connect
16th Jan 20194:22 pmRNSApplication for Admission
14th Jan 20197:00 amRNSYear-end Trading Update
13th Dec 20184:48 pmRNSScrip Dividend Circular (the "Circular")
30th Nov 20183:10 pmRNSTotal Voting Rights
20th Nov 20181:44 pmRNSApplication for Admission
6th Nov 20187:00 amRNSCapital Markets Seminar and Trading Update
1st Nov 20182:56 pmRNSTotal Voting Rights
18th Sep 20186:20 pmRNSDirector/PDMR Shareholding
14th Sep 201812:06 pmRNSResults of Placing
14th Sep 20187:00 amRNSAcquisitions and Placing of New Ordinary Shares
10th Sep 20183:18 pmRNSBlock Listing Six Monthly Return
31st Aug 20183:39 pmRNSTotal Voting Rights
24th Aug 201811:17 amRNSHalf-year Report
1st Aug 201811:54 amRNSTotal Voting Rights
26th Jul 20187:00 amRNSHalf-year Report
13th Jul 20182:34 pmRNSApplication for Admission - scrip dividend shares
13th Jul 20182:18 pmRNSDirector Declaration
21st Jun 20181:52 pmRNSResult of AGM
18th Jun 20183:37 pmRNSHolding(s) in Company
12th Jun 20184:41 pmRNSDirector/PDMR Shareholding
8th Jun 20183:45 pmRNSScrip Dividend Circular
1st Jun 201812:31 pmRNSTotal Voting Rights
21st May 20186:10 pmRNSNotice of AGM
17th May 20187:00 amRNSTrading Update
9th May 20187:00 amRNSBoard Changes
9th May 20187:00 amRNSBlock Listing Six Monthly Return
1st May 201811:45 amRNSTotal Voting Rights and Capital
20th Apr 201812:15 pmRNSDirector/PDMR Shareholding
20th Apr 201812:14 pmRNSDirector/PDMR Shareholding
18th Apr 20184:29 pmRNSNotification of Transactions
29th Mar 201810:50 amRNSTotal Voting Rights
22nd Mar 20185:01 pmRNS2017 Annual Report
9th Mar 20183:54 pmRNSDirector/PDMR Shareholding
6th Mar 201810:18 amRNSBlock Listing Six Monthly Return
5th Mar 20185:06 pmRNSDirector/PDMR Shareholding
28th Feb 20187:00 amRNSFinal Results
31st Jan 20189:40 amRNSTotal Voting Rights
12th Jan 201810:30 amRNSApplication for Admission - scrip dividend shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.